Skip to main content
. Author manuscript; available in PMC: 2013 Oct 30.
Published in final edited form as: J Psychiatr Res. 2010 Sep 9;45(4):10.1016/j.jpsychires.2010.07.011. doi: 10.1016/j.jpsychires.2010.07.011

Fig. 4.

Fig. 4

a: Levels of Aβ (1–40): Levels of Aβ (1–40) were assayed in all CSF samples by the sensitive sandwich ELISA method. An equal volume (5 μl) of CSF samples was loaded in the antibody pre-coated 96-well ELISA plate. Samples were incubated overnight and processed as described in ‘Materials and Methods’. Independent t-test showed no change in Aβ (1–40) level in the CSF of NPH patients (p = 0.120). b: Levels of Aβ (1–42): ELISA of Aβ (1–42) with 50 μl of CSF samples was carried out as mentioned in ‘Materials and Methods’ and Fig. 4a. Statistical analysis showed a significant decreased Aβ (1–42) level in the CSF of NPH vs. NNC subjects (p = 0.017). c: Separate analysis showed a further decrease in the magnitude of CSF Aβ (1–42) in NPH patients who are suffering from more than one year, vs. NNC (p = 0.002). d: Relative proportion of Aβ (1–40) and Aβ (1–42): Ratio of levels of Aβ (1–40) and Aβ (1–42) showed no significant change in the CSF samples of NPH patients, vs. NNC (p = 0.197).